Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2
Viruses · 29.04.2026 · 18 (5) · 509
DOI: 10.3390/v18050509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 29.04.2026. Verfasst von Lina Shalaby und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Wayne State University, Detroit, MI 48201, USA. Hauptthemen laut MEDLINE: Furin, Antiviral Agents, Dengue Virus, SARS-CoV-2. Die Arbeit nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar Research, Development and Innovation Council, Academic Research, Qatar Research, Development and Innovation Council.
Abstract (Originalsprache)
Dengue virus (DENV) and SARS-CoV-2 are emerging viral pathogens that share overlapping clinical features, including fever, fatigue, and respiratory symptoms, complicating differential diagnosis in endemic regions. Their co-circulation has increased the risk of co-infections, which may result in unpredictable disease progression, increased morbidity, and mortality. This overlap presents a significant challenge in managing outbreaks, as both viruses pose a major public health threat. Vaccines and direct-acting antivirals may be rendered ineffective by viral mutations, making it difficult to address evolving strains. Host-directed antivirals offer a promising alternative, potentially maintaining efficacy against a multitude of variants. Both DENV and SARS-CoV-2 rely on host proteases for viral maturation and entry, with furin playing a crucial role in viral glycoprotein cleavage. In DENV, furin cleaves the prM protein, facilitating virion maturation, while in SARS-CoV-2, the polybasic furin cleavage site in the spike protein enhances viral entry. This makes furin a compelling pan-viral target, where inhibiting furin could reduce viral fitness without relying on viral mutations. This review highlights the therapeutic rationale for targeting furin and discusses luteolin, a furin inhibitor showing antiviral activity against both viruses. Furin-targeted therapies may offer a durable antiviral strategy effective across DENV serotypes, SARS-CoV-2 variants, and co-infection settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Wayne State University, Detroit, MI 48201, USA.
- Basic Medical Sciences Department, College of Medicine, Qatar University Health, Qatar University, Doha P.O. Box 2713, Qatar.
- Biomedical Research Center, Qatar University Health, Qatar University, Doha P.O. Box 2713, Qatar.
- College of Health Sciences, Qatar University, Doha P.O. Box 2713, Qatar.
ORCID-Profile: Lina Shalaby, Hadi Yassine
Förderung
- Qatar Research, Development and Innovation Council, Academic Research
- Qatar Research, Development and Innovation Council
Zitieren
APA
Shalaby, L., Al-Haneedi, Y., Abdelhamid, A., Yassine, H., & Emara, M. M. (2026). Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2. Viruses, 18(5), 509. https://doi.org/10.3390/v18050509
Vancouver
Shalaby L, Al-Haneedi Y, Abdelhamid A, Yassine H, Emara MM. Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2. Viruses. 2026;18(5):509. doi:10.3390/v18050509
BibTeX
@article{Shalaby2026,
author = {Shalaby, Lina and Al-Haneedi, Yaman and Abdelhamid, Alaa and Yassine, Hadi and Emara, Mohamed M},
title = {Furin as a Novel Pan-Viral Therapeutic Target: Implications for Dengue and SARS-CoV-2},
journal = {Viruses},
year = {2026},
volume = {18},
number = {5},
pages = {509},
doi = {10.3390/v18050509}
}
EUVIMED